• Signed written informed consent
• 18 years of age or older
• ECOG performance status of 0 or 1
• Confirmed locally advanced or metastatic solid tumor with TP53 Y220C mutation by tumor tissue or liquid biopsy
• Patients with primary CNS tumors are eligible
• Patients with castration-resistant prostate cancer must be on ongoing androgen deprivation therapy
• Adequate organ function
• Life expectancy of at least 3 months as judged by Investigator

• Patients with ovarian, breast, lung, or endometrial tumors eligible for the PYNNACLE Phase 2 trial unless that cohort is closed
• Use of systemic anticancer therapies or investigational agents within 21 days or 5 half-lives prior to first study dose
• Radiotherapy within 14 days of first study dose except limited palliative or stereotactic body radiation to non-target lesions
• Use of inhibitors or inducers of enzymes and transporters tested in study within 14 days of study start
• Use of sensitive CYP3A4 or CYP2C8 substrates with narrow therapeutic index within 14 days
• Use of herbal medicines known to strongly affect CYP3A4 within 14 days
• Consumption of foods or drinks with CYP3A inhibition potential within 14 days
• Known allergy or intolerance to rezatapopt, metformin, rosuvastatin, repaglinide, midazolam, or similar substances
• Untreated brain metastases, leptomeningeal metastases, or spinal cord compression; prior treated brain metastases allowed if stable and >4 weeks
• Stroke or transient ischemic attack within 6 months before screening
• Uncontrolled or significant heart diseases including QTcF >470 msec or uncontrolled hypertension
• Active gastrointestinal diseases affecting drug absorption or metabolism
• History of organ transplant
• Other active invasive cancers within 2 years except certain treated local tumors
• Active uncontrolled hepatitis B, hepatitis C, or HIV infections
• Known KRAS single-nucleotide variation mutation
• Major surgery within 4 weeks of first study dose except vascular access placement

Other protocol-defined criteria may apply